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While most testicular germ cell tumours (TGCTs) exhibit exquisite sensitivity to platinum
chemotherapy, ~10% are platinum resistant. To gain insight into the underlying mechanisms,
we undertake whole exome sequencing and copy number analysis in 40 tumours from 26
cases with platinum-resistant TGCT, and combine this with published genomic data on an
additional 624 TGCTs. We integrate analyses for driver mutations, mutational burden, global,
arm-level and focal copy number (CN) events, and SNV and CN signatures. Albeit pre-
liminary and observational in nature, these analyses provide support for a possible
mechanistic link between early driver mutations in RAS and KIT and the widespread copy
number events by which TGCT is characterised.
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Testicular germ cell tumours (TGCTs) are the most com-mon cancer affecting young men, with peak incidence atage 30–36 years1,2. While cure rates for TGCTs are gen-
erally high due to their exquisite sensitivity to platinum-based
chemotherapies, options are limited for the ~10% of patients who
are platinum resistant, a group for whom the long-term survival
rate remains poor3,4. Upfront identification of patients who are
likely to be platinum resistant offers opportunities for tailoring
management and leveraging targetable molecular dependencies
for new treatments.
The major TGCT histologies are seminomas, which resemble
undifferentiated primary germ cells, and non-seminomas, and
show varying degrees of differentiation5. Approximately 5% of
GCTs are diagnosed at extragonadal sites and display the same
spectrum of histological types. Nonseminomas, and in particular
extragonadal nonseminomas are associated with a lower rate of
response to platinum6,7.
TGCTs are characterised by hypertriploid to subtetraploid
karyotypes featuring multiple aneuploidies. Gain of chromosome
arm 12p is a near universal feature, along with elevated rates of
reciprocal copy number changes. Frequent arm-level gains target
chromosome 7,8,21,22 and X8–10. TGCTs have a low frequency of
recurrent somatic mutations, with KIT and KRASmutations most
consistently reported as driver genes9–16.
The molecular basis of platinum response in TGCT remains
poorly understood. Defective homologous recombination and
mitochondrial priming have both recently been proposed as
possible mechanisms12,17–19. Increased frequency of TP53
mutation and higher mutational burden has variously been
reported in resistant tumours13,14. However, previous compar-
isons between resistant and sensitive tumours have provided
inconsistent data, based on small sample series with failure to
account for differences between series in histology, stage, site and
sequencing platform12–14,20,21.
Here, we present whole exome-sequencing (WES) on 40
tumours from 26 cases with platinum-resistant TGCT, the largest
series to date, along with molecular inversion probe (MIP) ana-
lysis for copy number. We combine these data with published
TGCT sequencing studies on 624 tumours from 605 cases,
undertaking multifactorial logistic/linear regression analysis,
adjusting for major clinical variables and other sources of bias.
From this we present a comprehensive survey of the genomic
landscape of TGCT to define the molecular hallmarks associated
with response to platinum-based therapy.
Results
ICR2 series of platinum-resistant tumours. We recruited a
series of TGCT cases with platinum-resistant disease
(ICR2 series), defined as showing progressive or viable disease
following one or more completed regimens of platinum-based
chemotherapy (Supplementary Table 1) and collected all available
TGCT specimens for these cases. Following application of pre-
sequencing and post-sequencing quality metrics, data for 22
primary and 18 metastatic tumours from 26 TGCT cases were
included, comprising sequence data from 189,028 exons from
23,585 genes, and MIP analysis, targeting genome wide copy
number aberrations (CNAs) in a subset of 33 tumours from 22
cases. We identified in total 1472 somatic small variants, com-
prising 1450 single nucleotide variants (SNVs) and 22 small
insertion–deletion (indel) variants, of which 964 were non-
synonymous, along with 792 arm level and 1035 focal gain/losses.
Additional TGCT series. We combined ICR2 WES data with
three previously published WES datasets to generate a combined
WES series of 290 TGCTs from 267 cases including 48 (18%)
with platinum-resistant disease (26 ICR2+ 22 DFCI). We also
made use of mutation panel sequencing data for 261 cancer genes
from two additional studies comprising 374 TGCTs from 364
cases (including 196 (54%) with platinum-resistant disease). In
total, the full sample series from the six studies provided infor-
mation on 664 tumours (444 primary, 220 metastatic) from 631
TGCT cases including 244 (39%) with platinum-resistant disease
(Fig. 1 and Supplementary Fig. 1; Supplementary Tables 2, 3;
Supplementary Data 1). For analyses requiring a single sample
per TGCT case, a representative (index) sample was selected.
Burden of small coding variants. Across the combined WES
series (290 TGCTs), a total of 4166 nonsynonymous variants and
1654 synonymous/noncoding somatic variants were detected,
equating to a mean total mutational burden of 0.43Mb (range
0–13.0 Mb) and a mean nonsynonymous mutational burden
(TMB) of 0.33Mb (range 0–9.4 Mb); results broadly similar to
those previously documented9–12 (Supplementary Data 2, 3;
Supplementary Fig. 1a). In multifactorial adjusted analysis
including adjustment for purity, TMB was significantly higher in
platinum-resistant than in sensitive TGCTs (p= 0.01), with a
mean increase of ~0.35 nonsynonymous mutations per megabase.
This association remained significant when the analysis was
confined to index primary tumours (p= 0.003), suggesting pre-
dictiveness in primary tumour for platinum resistance of TMB
(Fig. 2). There was no significant association of TMB with his-
tological subtype (p > 0.1 in all analyses, Supplementary Fig. 2).
TMB was positively correlated with age at diagnosis, more pro-
minently in nonseminomas (cor= 0.43, p-value= 0.0002), than
seminomas (cor= 0.17, p-value= 0.17).
Identification of driver genes. To identify TGCT driver genes,
we applied two complementary algorithms, OncoDriveFML22
and MutSigCV23 to index tumours in the combined WES series
(267 tumours) and further explored their mutation frequency and
distribution by integration of sequence data on 261 cancer genes
from the full sample series (631 tumours). KRAS and KIT had the
strongest evidence as driver genes from the combined analyses
and, followed by NRAS, were the most frequently mutated genes
(Fig. 3a and Supplementary Data 4 and 5; Supplementary Figs. 1a,
3). All three genes showed predominantly clonal mutation con-
sistent with truncal events (Supplementary Data 6). We identified
additional putative driver genes including the oncogenes RAC1,
PIK3CA, CBL, and CTNNB1 and tumour suppressor genes
KMT2C, CREBBP, and BCOR (each p < 0.05 in either Onco-
DriveFML and/or MutSigCV analyses). Both TP53 and PTEN
were amongst the most frequently mutated genes in the full
sample series. However, owing to their significantly lower
mutational frequency in the exome analysis (TP53 p= 7.0 × 10−8,
PTEN p= 9.4 × 10−4 exome vs. panel data), these genes did not
emerge as significant in the driver gene analysis (Supplementary
Data 5).
Clinical-pathological associations of driver genes. Using mul-
tifactorial adjusted analysis, we identified a number of distinct
clinical and pathological patterns of association for mutations in
the (putative) driver genes (Fig. 3b and Supplementary Table 4).
Mutation of KIT was associated with platinum sensitivity (p=
0.0008) whereas TP53 mutation was associated with platinum
resistance (p= 0.03). Association with seminoma was found for
mutations in KIT, KRAS and NRAS and for putative oncogenic
driver genes CBL, RAC1, PIK3CA, and CTNNB1 (analysed jointly
due to lower frequency), p= 3.33 × 10−10, p= 1.41 × 10−6, p=
0.002, p= 0.009, respectively. TP53 mutation was associated with
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nonseminoma (p= 0.04). Mutation of KIT, KRAS, NRAS and
TP53 were each associated with extragonadal disease (p < 0.002).
Pathway analysis. To explore pathways implicated in TGCT
tumorigenesis, we organised known/putative TGCT driver genes
into mutually exclusive gene sets, namely RAS/RAF, PI3K/MTOR
and WNT/CTNNB1 signalling pathways, chromatin modification
and DNA repair, along with other genes within those pathways
carrying an oncogenic mutation. Mutation of WNT/CTNNB1
pathway genes was associated with platinum-resistant (p= 0.04)
and metastatic (p= 0.03) disease. The mutational profile was
consistent with upregulation of WNT signalling, with activating
mutations identified in CTNNB1 (n= 6), and inactivating muta-
tions in APC (n= 3), FAT1 (n= 3), AXIN1 (n= 1), and GSK3B
(n= 1)) (Fig. 3b, c). Association was also identified for RAS/RAF
with seminoma and extragonadal disease (p= 2.9 × 10−8 and p=
4.7 × 10−6, respectively) and PI3K/MTOR pathway with semi-
noma (p= 0.02, Fig. 3b).
Copy number analysis. Copy number analysis was performed on
the 188/256 primary TGCTs from the complete WES series for
which high quality copy number data, tumour purity > 40% and
complete clinical data were available (Supplementary Fig. 1b,
Supplementary Data 7, Supplementary Table 5). The majority of
tumours had hyperploidy (80% had ploidy >2.5) and exhibited an
elevated rate of arm-level amplifications (median number of
arms/tumour with ≥1 allele amplified = 9).
The most frequently observed individual arm-level events
included gain of 12p (95%) 21q (76%) and 7p (74%) and most
frequent focal events were amplification of 12p13.32 (96%),
12p12.1 (93%), and 12p11.21 (92%) (Supplementary Data 7).
In multifactorial adjusted analysis, no significant differences
were detected between platinum-sensitive and platinum-resistant
primary tumours in the frequencies of global, individual arm or
focal chromosomal aberrations (Fig. 4 and Supplementary Data 8,
9). Metastatic tumours showed an increased frequency of gains of
11p (30% vs. 3%, p= 0.03), 11q (30% vs. 3%, p= 0.03), 13q (30%
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Fig. 2 Tumour mutation burden in TGCT. Box plot showing that tumour mutation burden (TMB) is higher in platinum-resistant tumours vs. platinum-
sensitive/unselected tumours (a, b) and metastatic tumours vs. primary tumours (c, d). Analyses were performed on 269 tumours with exome sequencing
data (from the ICR1, ICR2, DFCI, and TCGA sample series) after excluding those samples with missing histology and/or missing tumour purity estimate
(n= 20), and one sample with an excessively high TMB (DFCI_C13_T1) (n= 269, a, c). Analyses were also restricted to a subset of tumours comprising
either only primary tumours (n= 239, b) or tumours from cases with platinum resistant disease (n= 64, d). Boxes show the median ± 25–75th percentiles,
whiskers show 1.5× interquartile range below and above the 25th and 75th percentiles, respectively. p values are derived via two-sided multiple linear
regression models adjusting for sample stage, histology, platinum response, dataset, and tumour purity.
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Fig. 1 Study overview. We combined data from six tumour sequencing studies of TGCT, performing small variant, copy number and tumour evolution
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Fig. 3 Mutational landscape of cancer driver genes in TGCT. a Oncoplot showing the cancer driver genes most frequently mutated across 631 index
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(n= 207). b Oncogenic mutation frequencies in individual genes/gene sets across index TGCTs with the relevant available data, comparing: platinum-
sensitive/unselected (n= 284, orange) vs. platinum-resistant (n= 244, red) tumours; primary (n= 435, dark blue) vs. metastatic (n= 196, light blue)
tumours; seminomas (n= 204, yellow) vs. nonseminomas (n= 417, purple); and testicular (n= 584, black) vs. extragonadal (n= 47, green) primary
sample site. Asterisks denote p values derived from two-sided multivariable logistic regression, adjusting for platinum response, histology, stage, capture
type, sample material and primary sample site.*p < 0.05, **p < 0.01, ***p < 0.001. Exact p values are provided in Supplementary Table 4. Putative TGCT
genes: CBL, RAC1, PIK3CA, KMT2C, CREBBP, BCOR and CTNNB1. c WNT/CTNNB1 pathway alterations are overrepresented in platinum-resistant metastatic
TGCTs (n= 22) with the majority consistent with pathway activation. Pathway components that negatively regulate CTNNB1 are shown in green.
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Fig. 4 Autosomal arm level aneuploidy frequencies. The frequency of whole arm autosomal aneuploidy events in 183 TGCTs with available copy number
data and tumour purity ≥ 0.4 from series ICR1, ICR2, DFCI and TCGA, comparing platinum-sensitive/unselected (orange, n= 134) vs. platinum-resistant
(red, n= 29) primary TGCT, and comparing primary (dark blue, n= 29) vs metastatic (light blue, n= 20) platinum resistant TGCT (only a single
representative metastatic tumour from each patient with platinum resistant TGCT was included-see Supplementary Data 7). Asterisks denote p values
derived from two-sided multivariable logistic regression: *p < 0.05, **p < 0.01, Exact p values are provided in Supplementary Data 8.
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vs. 3%, p= 0.03), 20p (50% vs. 17%, p= 0.01) and 20q (70% vs.
28%, p= 0.004), loss of 21q (25% vs. 3%, p= 0.05), as well as
focal amplification of 20q11.21 (65% vs. 34% p= 0.03) and focal
deletion of 1p36.21 (25% vs. 33%, p= 0.01) (Fig. 4 and
Supplementary Data 8 and 9).
We also assessed absolute copy number for each of the known
and putative TGCT genes along with MDM2, MYCN and FSIP
(which have previously been reported to be focally amplified in
TGCT9,10,13) (Fig. 5 and Supplementary Table 6). KRAS, RAC1
and MDM2 were the genes most frequently affected by copy gain
(5+ copies per tumour in 86%, 24% and 21%, respectively) whilst
CBL, TP53 and CREBPP were the genes most frequently affected
by copy loss (0 or 1 copies in 20%, 5% and 4%, respectively).
Multifactorial adjusted analysis did not identify any significant
associations with platinum response for gain/loss of specific
genes, individually or in combination (Supplementary Table 6)
Mutational signatures. We next examined signatures of muta-
tional processes to gain insights into the molecular development
of TGCT (Supplementary Fig. 1a). We analysed the 247 primary
TGCTs with histolgy from the combined WES series for the 30
SNV mutational signatures defined by COSMIC24 (Fig. 6 and
Supplementary Data 10). SNV Signature 3 (SNV-Sig-3), indica-
tive of failure of DNA double-strand break-repair by homologous
recombination, was the predominant SNV signature in TGCTs,
accounting for up to 40% of the mutational contribution (Fig. 6
and Supplementary Data 10). Markedly lower levels of SNV-Sig-3
were observed in platinum-resistant tumours. Conversely, SNV-
Sig-1 was absent in platinum sensitive/unselected seminomas
(Fig. 6 and Supplementary Data 10). Seminomas typically show
global hypomethylation whilst nonseminomas exhibit increased
methylation associated with increased differentiation from
embryonal carcinoma through to teratoma. SNV-Sig-1 is thought
to reflect spontaneous deamination of 5-methylcytosine. The
absence of SNV-Sig1 observed in platinum sensitive/unselected
seminomas is thus in fitting with existing hypotheses of
association in cancer between differentiation, global DNA
methylation status and response to chemotherapy25,26.
We performed sample-level SNV signature analysis for in the
17 tumours carrying ≥50 mutations, of which 16 were platinum
resistant and 12 were metastatic. In the 12 platinum resistant
metastatic samples, SNV-Sig-3 was present in nine and
predominant in five (Supplementary Data 10). The median value
of SNV-Sig-3 in these 12 tumours was 0.13 (interquartile range:
0–0.37).
We next examined copy number signatures using non-negative
matrix factorisation (NMF) as previously described27. We first
applied the methods to fresh tissue samples of purity ≥0.4 with
available array genotyping data (n= 105, TCGA, unselected
TGCTs) (Supplementary Fig. 1b). Using random permutations of
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Fig. 5 Absolute copy number of driver genes. Plot showing the absolute copy number in 183 TGCTs with available copy number data and tumour purity
≥0.4 (ICR1, ICR2, DFCI and TCGA sample series) for fourteen genes including the putative/known TGCT driver genes (KIT, KRAS, NRAS, RAC1, CBL,
PIK3CA, CREBBP, KMT2C, CTNNB1), TP53 and PTEN, and three genes previously implicated as focally amplified in TGCT, namely FSIP2, MDM2 and
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Fig. 6 COSMIC mutational signatures. COSMIC SNV mutation signatures
identified in TGCT, organized by histology and platinum response. Analyses
were performed on 247 primary tumours with exome sequencing data
(ICR1, ICR2, DFCI and TCGA series) after excluding nine primary tumours
with missing histology. Signatures were derived from somatic SNVs from
primary tumours pooled together within each group as indicated. COSMIC
signatures 1, 3 and 19 are displayed separately, whilst other represents the
contribution from the remaining signatures combined.
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the data and four model selection measures, we found the optimal
number of signatures in the TGCT dataset to be five, and each
signature was present at >5% in 74–91% of TGCTs and shared
highly similar component weights to those previously reported
(p < 5.9 × 10−9, r2 ≥ 0.8) (Fig. 7 and Supplementary Data 11;
Supplementary Tables 7, 8; Supplementary Fig. 4)27.
CN signature 1 (CN-Sig-1), characterised by large segment
sizes and low breakpoint frequency (0-2 breakpoints per
chromosome arm), was the predominant signature and was
higher in seminomas positive for mutations in KIT (p= 0.004)
and RAS mutations (KRAS and NRAS combined, p= 0.07)
(Fig. 7c), recapitulating the association of mutations in the RAS/
MAPK signalling pathway with CN-Sig-1 reported in serous
ovarian carcinomas27. The next most significant signature
exposure was CN-Sig-3, characterised by evenly distributed
chromosome breaks and diploid-to-single copy changes (i.e., loss
of heterozygosity), which in ovarian carcinoma was associated
with defective homologous recombination and somatic/germline
BRCA1/2 mutation27.
Both CN-Sig-4 and CN-Sig-6 have previously been associated
with failure of cell cycle control, and were shown to be associated
with seminoma histology (p < 0.007; Supplementary Fig. 4c).
Notably CN-Sig-6, which reflects high copy number states from
focal amplification, was particularly high in seminomas with (i)
increased 12p copy number, (ii) KRAS copy number and/or, (iii)
KRAS mRNA expression (without KIT/KRAS/NRAS mutations)
(Fig. 5b and Supplementary Table 8). Also identified was CN-Sig-
5, which is characterised by subclonal copy number changes and a
large number of breakpoints per chromosome arm; CN-Sig-5 is
proposed to reflect chromothriptic-like events and/or increased
subclonal diversity. We found CN-Sig-5 to be associated with
MDM2 expression in nonseminomas (p= 0.00008) and to be
correlated with age at diagnosis in seminomas (p= 0.01).
We next applied CN signature analysis to a second series of
cases in which copy number had been called from fresh-tissue-
derived WES data (n= 19, ICR1, unselected TGCTs). Detection
of the same five CN signatures was reproduced, along with the
associations by histological subtype (Supplementary Table 9;
Supplementary Fig. 4c). However, detection of the CN signatures
was less delineated in FFPE-derived sample series ICR2 and
DFCI, preventing analysis of potential differences in CN signature
exposure between platinum-sensitive vs platinum-resistant
tumours (Supplementary Table 9).
Longitudinal analysis of platinum-resistant tumours. Restrict-
ing analysis to those platinum-resistant cases for which serial
samples were available, we analysed 39 tumours from 17 indivi-
duals (ICR2, DFCI).
Overall, for the 1126 unique SNVs identified, there was wide
variability between patients in their inter-tumour mutational
concordance (Jaccard index ranged from 2 to 92) (Supplementary
Table 10; Supplementary Fig. 5). We performed gene function
enrichment analysis on nonsynonymous mutations grouped by
whether they were (i) truncal events (i.e., shared between primary
and metastatic tumours), (ii) private amongst pre-treatment
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Fig. 7 TGCT copy number signatures. Five copy number signatures (CN-Sig-1, CN-Sig-3, CN-Sig-4, CN-Sig-5, CN-Sig-6) identified using TCGA SNP array
data (n= 105). a Defining features of the CN signatures, showing each feature (SegSize, osCN, ChangePoint, BP10, CopyNumber and BPChr) split into 36
constituent components, as defined in ref. 27. The mean value for each component is shown on the x axis, with component weights shown on the y axis.
Features are defined as follows: SegSize, segment size (Mb); ocCN, region length with neighbouring oscillating copy number segments (Mb); ChangePoint,
difference in copy number between neighbouring segments; BP10, number of break points (10Mb−1), CopyNumber, absolute copy number of segment;
BPChr, breakpoints per chromosome arm. b CN signature exposure correlations with clinical and molecular features. Two-sided Pearson’s correlations for
association of q < 0.05 are illustrated. Age, aneuploidy and chromosome 12p copies: analysed across histologies. RAS pathway-related features: analysed in
seminomas only. c Box plots showing CN signature exposure comparisons for KIT (n= 12) and RAS (n= 7, NRAS/KRAS) mutated seminomas, wildtype
seminomas (n= 18) and nonseminomas (n= 66). Boxes show the median ± 25–75th percentiles, whiskers show 1.5× interquartile range below and above
the 25th and 75th percentiles, respectively. p values are derived from two-sided Wilcoxon Rank Sum tests adjusted for multiple comparisons via the
Benjamini-Hochberg method.
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primary tumours or (iii) private amongst post-treatment meta-
static tumours. Notable gene sets enriched in truncal events
include those associated with DNA binding (GO-MF:0003677; p
= 0.003), nucleobase metabolism (GO-BP:0019219; p= 0.05),
and base excision repair (KEGG:03410; p= 0.03) (Supplementary
Data 12). No gene set enrichments were found for nonsynon-
ymous variants private to primary tumours or for silent
mutations in any group.
We performed phylogenetic analyses on large-scale CNVs
identified in ICR2 primary and metastatic samples using
MEDICC (Minimum Event Distance for Intra-tumour Copy
number Comparisons)28,29. This revealed evidence for branched
evolution in the vast majority of cases (Supplementary Figure 6).
In the two cases where data was available for multiple metastatic
tumours, the metastatic samples descended from a single
common metastatic precursor. Metastatic samples showed
continued acquisition of copy number aberrations, and a linear
relationship was observed between the number of CN events and
number of months since initial diagnosis when looking across all
metastatic samples (Supplementary Table 11; Supplementary
Fig. 7; r2= 0.70; p= 0.02).
Discussion
Platinum-resistant TGCT remains an unsolved clinical pro-
blem30. We have assembled the largest WES series to date of
platinum-resistant tumours (n= 40, ICR2), with which we have
integrated five additional series to present data on 664 tumours,
far and away the largest TGCT series analysed to date. In sum-
mary, we demonstrate via multifactorial analysis adjusted for
clinical and technical confounding factors, that there is significant
difference between platinum-sensitive and platinum-resistant
tumours in frequency of (i) KIT mutation, (ii) TP53 mutation,
(iii) mutations in WNT/CTNNB1 signalling genes, and (iv)
mutational burden of nonsynonymous small variants. Further-
more, we delineate the prominence in TGCT of mutational sig-
natures indicative of HRD (SV-Sig-3, CN-Sig-3) and RAS-related
structural aberration (CN-Sig-1). Integrating the full data from
platinum sensitive and platinum resistant tumours, we can distil
into seven molecular hallmarks our current understanding of
TGC tumorigenesis and platinum response.
Firstly, TGCTs are characterised by a TMB substantially lower
than that of other adult solid tumours and more consistent with
paediatric embryonal tumours. Consistent with the proposed
embryonal aetiology of TGCT, TMB is correlated with age of
tumour diagnosis. Previous reports have highlighted a higher
TMB observed in post-chemotherapy metastatic samples as
compared to treatment-naïve (subsequently platinum-sensitive)
TGCTs: the direct effects of chemotherapy on TMB cannot be
partitioned here13,14. We demonstrate that in primary TGCT,
TMB is significantly higher in platinum-resistant tumours,
independent of subsequent chemotherapy treatment. This
strongly suggests that treatment resistance may be a consequence
of other mutational processes that provide a larger substrate of
genetic variation that increases the chances of evolutionary res-
cue. Intriguingly, we found enrichment amongst truncal events of
mutations in genes involved in inter-strand crosslink resolution.
TMB itself is widely accepted to be a barometer of neoantigen
load and tumour immunogenicity. Consistent with this, there are
several case reports in platinum-resistant TGCTs of response to
checkpoint inhibitors (reviewed in ref. 31); nevertheless, detailed
correlation against expression of specific antigens has yet to be
performed.
Secondly, the small variant landscape of TGCT is dominated
by mutation of KIT and RAS/RAF-pathway genes. Through
adjusted analysis, we delineate independent association with
seminoma histology for mutations in KIT, KRAS, NRAS and
Pi3K/MTOR pathway gene sets and, independent of histology,
association of KIT mutation with platinum sensitivity. This
enrichment in seminomas is consistent with mutation of KIT and
its downstream effectors occurring at an early stage of TGC
tumorigenesis and blocking differentiation from the inherently
platinum-sensitive PGC-like seminomatous state10.
Small migratory populations of primordial germ cells (PGCs)
first arise in the early embryo and pass through various
embryonic tissues on their way to the nascent gonad32. Extra-
gonadal GCTs, located along the PGC migration path, likely
reflect disruption to this process. In adjusted analysis, we
observed enrichment in extragonadal GCTs compared to gonadal
GCTs for all TGCT driver genes and pathways analysed (KRAS,
KIT, NRAS, seven putative driver genes, other RAS/RAF pathway
genes), providing support for the hypotheses that TGCT driver
mutations (i) typically arise prior to PGC separation and (ii)
increase the probability that a PGC will become misplaced. Model
organisms with mutations in genes orthologous to KIT and TP53
display an increase in PGCs outside the gonad, supporting the
importance of correct migration and survival of PGCs for these
genes33.
Indeed, the third hallmark of TGCT is the overall low fre-
quency of somatic TP53 mutation (6.7%), with mutations iden-
tified predominantly in non-seminomatous TGCTs and
extragonadal TGCTs (both parameters strongly associated with
platinum resistance). Following adjustment for the confounding
influences of site, histology and sequencing platform, the inde-
pendent association of TP53 mutation with platinum resistance is
marginal (p= 0.03), a result that contrasts with previous unad-
justed analyses. Furthermore, there was no association (p= 0.81)
with platinum resistance of amplification of MDM2, a TP53
antagonist amplified in a sizeable proportion (20%) of TGCTs.
We identified association between TP53 mutation and panel
sequencing methodology, residual after adjustment for potentially
confounding parameters. TP53 variant allele frequencies were
typically high, and coverage of TP53 was sufficiently adequate in
the exomes, to rule out differential detection of subclonal TP53
mutations between the two methods. It is possible the observed
association may be due to confounding factors unaccounted for
in these analyses, for example systematic differences in the clin-
ical make-up of the constituent sample series.
The fourth hallmark of TGCT is aberration of the WNT/
CTNNB1 signalling pathway, with enrichment for somatic WNT/
CTNNB1 pathway mutations detected in both platinum-resistant
and metastatic TGCTs. Previous immunohistochemical and
expression analyses have exhibited upregulation of WNT/
CTNNB1 signalling in TGCTs, particularly nonseminomas10,34,35.
The WNT/CTNNB1 pathway plays an important role in multiple
developmental processes and stemness and is upregulated in many
other cancer types.
Fifthly, TGCTs are characterised by dramatic and widespread
structural aberration. Early nondisjunction results in whole gen-
ome doubling and a tetraploid precursor cell, followed by gain
and loss of multiple large chromosomal regions, most frequently
isochromosome 12p. Like HGSOC, the extreme genomic com-
plexity of TGCT has hampered mechanistic understanding of the
aetiology/consequences of CN aberrations. Using CN signature
analysis, we have been able to relate patterns of CN aberration to
potentially causative molecular phenomena (Fig. 7).
For example, the high frequency of large but sub-whole arm
exchanges in TGCTs is reflected in a high level of CN-Sig-1. We
demonstrate clear association in seminomas of CN-Sig-1 with
KRAS/NRAS/KIT-mutation, a phenomenon also observed in
HGSOC27. Aberrant RAS signalling promotes genomic instability
due to aberrant cell cycle checkpoint control leading to
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chromosomal missegregation36,37. In HGSOC, CN-Sig-1 is
directly correlated with telomere shortening and frequency of
amplification-associated fold-back inversion events, pointing to
the underlying mechanism as breakage-fusion-bridge27. In
keeping with these observations, telomeric shortening is a con-
sistent feature of KIT/RAS mutated seminomas38.
Meanwhile, compared to KIT/RAS mutated tumours, wildtype
seminomas exhibit strong exposure of CN-Sig-6 (indicating focal
amplification with high copy number states). Rather than a mere
passenger effect, the focal amplification and upregulation of
KRAS in these wildtype seminomas may instead reflect an active
alternative mechanism by which RAS signalling has been
increased.
The sixth hallmark of TGCT is that progression and metastasis
in resistant tumours are characterised by evolving aberration of
copy number. Supported anecdotally via longitudinal phyloge-
netic analysis in select serially sampled tumours (n= 5)12, we
have now demonstrated this via systematic comparison across the
series of primary and metastatic tumours. In particular, gain of
chromosome arm 20q and focal amplification of 20q11.21 are
each present in 65–70% of metastatic TGCT, representing sta-
tistically significantly elevated rates compared to primary resis-
tant tumours. Recurrent gain of 20q has been observed across
numerous cancer types and metastatic behaviour is associated
with amplification of different sub regions of 20q39–43. Gain of
20q11.21 is very frequent in human embryonic stem cell (hESC)
lines, human embryonal carcinoma cell lines and some ter-
atocarcinomas44, and may confer protection against apoptosis as
a result of BCL2L1 overexpression45,46, as well playing a role in
malignant transformation45.
Finally, homologous recombination deficiency (HRD) would
appear to be a universal feature of TGCT, as exemplified by our
observation of marked predominance of SNV-Sig-3 along with
prominence of CN-Sig-3. Whilst we and others have found a low
frequency of coding mutations in genes involved in homologous
recombination repair, epigenetic silencing is a plausible under-
lying mechanism as a high frequency of inactivation by methy-
lation of BRCA1 and RAD51C has been reported in TGCTs10,17.
Whilst signature assignation at cohort level indicates pre-
dominance of SNV-Sig-3 with inverse association with platinum
resistance, robust insight into the aetiological contribution of
HRD to TGCT and platinum response will require individual
sample level analysis with de novo signature extraction, assiduous
signature fitting and adjustment for confounding covariates47. On
account of the low frequency of somatic mutation in TGCTs,
whole genome rather than exome analysis will be required to
further explore our preliminary observations.
Limitations of our study include the modest size of the
ICR2 series (40 samples, 26 cases), resultant from the overall low
frequency of TGCTs compounded by the small platinum-
resistant proportion therein. Furthermore, as platinum response
is only manifest downstream of diagnosis, only routine formalin-
processed clinical specimens were available pre-treatment. For
these same logistical reasons, very limited additional WES data
were available for resistant TGCTs (20 cases) with the majority of
molecular data from resistant TGCTs coming from routine
clinical diagnostic gene panels. Thus, beyond comparison of
frequency of specific small variants, the pan-genomic compara-
tive analysis of resistant versus sensitive disease remains limited
by power and sample preparation. Whilst we undertook multi-
factorial adjusted analysis to mitigate against the confounding
influence of variability in constituency of cases across the six
studies (histology, site, stage, specific study, sample preparation,
and capture-type), integrated analyses across studies was com-
promised by heterogeneity in molecular testing platforms, in
particular for analyses of copy number. The significant
associations observed may reflect causal relationship but may also
arise due to the influences of chance, bias, confounding or reverse
causality.
In conclusion, we have presented a comprehensive molecular
description of platinum-resistant and platinum-sensitive TGCTs
based on assembly of the largest integrated genomic dataset to
date. We demonstrate that platinum resistance cannot be
accounted for by a single molecular entity but is likely to involve
multiple mutational processes. To better understand these pro-
cesses, further large series of serial fresh-processed platinum-
resistant (and sensitive) TGCT samples are required with aligned
longitudinal clinical data. Whilst whole genome sequencing data
will be invaluable for additional exploration of the clinical and
molecular correlates of platinum response and SNV and CN
signatures, more comprehensive aetiological insight will likely
require epigenetic, transcriptomic and proteomic profiling.
Methods
Cases and samples. The ICR2 TGCT case series was ascertained and consented
via the UK Genetics of Testicular Cancer Study, which has been reviewed by the
Royal Marsden Hospital Committee for Clinical Research, Cancer Research UK
programmes committee and received ethical approval from the South West MREC
(research and ethics committee (06/MRE06/41). All patients provided written
informed consent. Patients already consented within this study were selected for
inclusion in the ICR2 series if platinum resistance was reported by the referring
clinician, that is after one or more complete regimens of platinum-based che-
motherapy there was progressive disease (relapse or incomplete response), or viable
(non-teratomatous) disease in a post-chemotherapy surgical sample. All docu-
mented tissue samples for these patients were sought via contact with the respective
pathology department. Stored formalin fixed paraffin embedded tumour tissue
samples (slides/blocks) were sent to our centre and material was retrieved by a
trained pathologist by macrodissection guided by hematoxylin and eosin-stained
slides. Tumour DNA was extracted using Qiagen’s QIAAMP® DNA FFPE tissue kit
(Qiagen, Hilden, Germany) following manufacturers protocols. Tumour DNA
samples were quantified and qualified using Qubit technology (Invitrogen, Carls-
bad, CA, USA) and the 2200 TapeStation System (Agilent, Santa Clara, CA, USA).
Matched normal DNA was obtained from lymphocytes using standard techniques.
We affirm compliance with all relevant ethical regulations for work with human
participants.
Other sample series were recruited as previously described9,10,12–14,48.
WES sample processing (ICR2). DNA libraries for ICR2 tumour-normal pairs
were prepared from 200 to 400 ng of DNA (depending on quality), using the KAPA
HyperPlus Kit (Roche, Basel, Switzerland) with seven PCR cycles following stan-
dardized protocols as per manufacturer guidelines. Exome capture (4-plex) was
performed using the SeqCap EZ HGSC VCRome kit (Roche, Basel, Switzerland)
following standardized protocols as per manufacturer guidelines. Samples under-
went paired-end sequencing using the Ilumina HiSeq2500 platform (Illumina, San
Diego, CA, USA) with a 100-bp read length. FASTQ files were generated using
Illumina CASAVA software (v.1.8.1, Illumina).
WES alignment and variant calling (ICR2 and DFCI). The ICR2 and DFCI whole
exome sequencing data were processed through a common informatics pipeline.
Sequence alignment was performed following GATK best practices. Raw unmap-
ped reads were aligned to build 37 of the human genome using BWA-MEM
(v0.7.12), and the resulting SAM files were converted to BAM files, and sorted and
indexed using SAMtools (v1.3). Picard Tools (v1.94) was used to merge BAM files
and to mark duplicates. Indel realignment and base quality were performed using
IndelRealigner and PrintReads, respectively (GATKv3.6). Somatic variant calling
was performed using Strelka (v1.0.14; for SNVs and indels), Mutect (v1.1.7; for
SNVs) and Mutect2 (GATKv3.6; for indels). A panel of normals was generated
using germline (normal) samples for use with Mutect and Mutect2. Variants were
retained for analysis if called by ≥2 calling algorithms. Artefacts introduced by
DNA oxidation during sequencing of FFPE were identified using the FoXoG
algorithm49 and removed. FoxoG ensured variants were supported by a minimum
of one alternative read in each strand direction, a mean Phred base quality score of
26, mean mapping quality greater than or equal to 50 and an alignability site score
of 1.0.
WES quality control (ICR2 and DFCI). The following filters were applied to
remove low quality samples: percentage of bases at 15× <50% (DepthOfCoverage,
GATKv3.6); samples with cross-individual contamination fraction >5% (ContEst,
GATK v3.6). NGSCheckMate (v1.0) was used to confirm that both samples from
each tumour-normal pair, and serial tumour samples for a given case, were from
the same individual50. Mean target coverage across the cohorts for tumours was
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130× and for normal samples was 97×. After the removal of two samples with
ContEst scores of >5%, the mean ContEst value was 0.52%.
WES SNV calls from other datasets (ICR1 and TCGA). ICR1 SNV calls were
generated as previously described9. TCGA SNV calls were obtained from the
BROAD Firehose browser51.
WES SNV hard filtering (ICR1, ICR2, DFCI and TCGA). Additional hard filters
were applied to the pooled set of SNV calls from the exomic datasets to remove
variant calls likely to be artefacts. SNVs were required to have five or more sup-
porting reads, indels were required to have ten or more supporting reads, and both
were required to have a variant allele frequency (VAF) of 0.05 or greater. Variant
calls were rescued if (a) they overlapped with known driver mutations documented
in OncoKB or (b) if they overlapped with a COSMIC alterations with a count of at
least n= 50. A variant was also rescued if it passed these filters in a second tumour
from the same individual. Any individual gene or variant with a mutation fre-
quency greater than or equal to 10% within a single dataset whilst simultaneously
having a frequency of less than 1% within each of the remaining datasets were also
removed on the basis that they were likely an artefact specific to that dataset.
Analyses of the combined WES series were restricted to variants located at the
intersect of the different captures (comprising ~30Mb of the genome), as deter-
mined using the intersect tool from bedtools (v2.25.0).
SNV calls from panel data (MSK, FDM). SNV data were incorporated from a
further two sources: (i) 278–315 genes analysed by Foundation Medicine, 107 cases
with platinum-resistant TGCT, as published14 and (ii) clinical sequencing data on
341–410 genes from 267 cases from Memorial Sloan Kettering patients (MSK-
IMPACT), as published13,48. Variants with ambiguous annotation in the Foun-
dation Medicine dataset were removed from all analyses.
Identifying likely TGCT driver genes. WES data: MutSigCV was employed to
identify genes from the combined WES series that are mutated more often than
one would expect by chance. This method corrects for variation by employing
patient-specific mutation frequencies and mutation spectra, and gene specific
mutation rates that incorporates covariate factors such as replication timing and
expression levels23. OncodriveFML was employed to look for evidence of positive
selection. This method works by estimating the accumulated function impact bias
of somatic mutations based on a local simulation of the mutational processes
affecting it22. Analyses were performed on a single representative (index) sample
from each case to avoid upward bias of results.
WES+ panel data: The total number of mutations identified across each of 261
cancer-associated genes common to all six WES and panel captures was calculated.
All somatic changes were annotated at variant-level as being of likely functional
significance if they were a known cancer driver alteration, as defined by their
presence in one three databases (i) OncoKB, a precision oncology knowledge base
hand curated by experts as described in ref. 52, (ii) Cancer Hotspots, a set of
significantly recurrently mutated residues identified by the algorithm described in
refs. 53,54 (iii) 3Dhotspot, a set of mutations that show evidence of clustering in 3D
protein structures identified by the algorithm described in ref. 55.
Genes were categorised with respect to their driver status in TGCT: Definitive,
gene passing at exome wide significance (q < 0.05) via both MutSigCV and
OncoDriveFML; Likely, gene passing at exome wide significance (q < 0.05) in
MutSigCV or OncoDriveFM; Putative, gene (a) showing nominal statistically
significant result in at least one algorithm (p < 0.05), (b) residing within the top 5th
centile of genes recurrently mutated by known cancer driver variants, (c)
comprising a predominance (>50%) of previously described driver variants.
KIT, KRAS and NRAS clonal status. We estimated the clonal status of mutations
in KIT, KRAS and NRAS as previously described56. We used variant allele fraction,
ploidy and purity values to calculate the multiplicity of each variant, that is the
number of alleles within a given tumour that carry a particular mutation, using
>0.8 as likely indicative of a mutation being clonal56.
Mutation status association analyses. We performed multivariable logistic
regression (i.e., multifactorial adjusted analysis) to examine the relationship
between gene mutation status and clinical characteristics including histology
(seminoma/nonseminoma), stage (primary/metastasis), tumour site (testis/extra-
gonadal), and platinum response (sensitive/unselected or resistant) whilst adjusting
for potential technical confounders including capture type (exome/panel) and
sample material type (fresh frozen/FFPE). Stepwise iterative analyses were per-
formed, whereby the variable with the least significant p value was removed from
the model, and this was performed until only statistically significant variables
remained. When a model contained a variable of interest with borderline sig-
nificance, we also performed likelihood ratio testing to evaluate whether inclusion
of the variable offered improved prediction of the data. Tests with a significant p-
value indicate that the reduced model is not a better fit of the data (i.e., that the
borderline associated variant should be included in the model). Logistic regression
was performed using the glm() function (binomial family with logit link) and
likelihood ratio testing was performed using the anova() function (with a chi-
squared test), via the R package stats (v3.5.1). These and subsequent R packages
were used in R (v3.5.1) via RStudio (v1.1.463).
Tumour mutation burden analyses. Tumour mutation burden was calculated on
a per sample basis as the number of mutations divided by the number of bases
within the intersected BED file, and given as the number of mutations per
megabase. Mutational burden was calculated both across all SNVs and by limiting
analysis to nonsynonymous mutations. Mutational burden comparisons were
performed on nonsynonymous mutation burden values using multiple linear
regression, with nonsynonymous mutational burden as the continuous outcome
and multiple categorical predictors, allowing us to assess the independence of
relationships whilst simultaneously adjusting for potential confounders. Catego-
rical predictors included in the model were dataset (ICR1, ICR2, DFCI, TCGA),
sample site (primary, metastatic), platinum response (sensitive/unselected, resis-
tant), histology (seminoma, nonseminoma), and whether multiple samples from a
single case were included (yes, no). Age at diagnosis, a potential cofounder, was not
included in the regression model due to substantial missingness across the datasets.
Analyses were performed in (a) all tumours, (b) primary tumours only and (c)
tumours from platinum resistant cases only. A single sample with an excessively
high mutational burden compared to the rest of the cases was excluded from these
analyses (DFCI_C13_T1). Analysis was performed using the lm() function from
the R package stats (v3.5.1). Supplementary to these analyses, we used an exact,
distribution free method using the lmp() function from the R package lmPerm
(v2.1.0), which uses permutation instead of normal theory.
Pathways analysis. Genes with oncogenic mutations were organised into signal-
ling pathways or cellular functions. Genes were assigned to pathways based on the
results of functional experiments in the primary literature. We focused on those
gene sets implicated by known/putative TGCT driver genes and comprised: RAS/
RAF signalling (KRAS, NRAS, BRAF, NF1); PI3K/MTOR signalling (PIK3CA,
PIK3CB, PIK3R1, PIK3R2, MTOR, RICTOR, AKT1, PTEN); WNT/
CTNNB1 signalling (CTNNB1, APC, AXIN1, GSK3B, FAT1); DNA repair (BRCA1,
BRCA2, ATM, CHEK2, PALB2, POLE, TOP1, BARD1, PMS2, MUTYH, BAP1,
CDK12) and chromatin modification (CREBBP, DNMT3A, NSD1, EP300, KMT2A,
SMARCB1, SMARCA4, SETD2, KMT2C, KDM6A, ASXL1, ARID1A, ARID1B,
ARID2, PBRM1).
COSMIC SNV signature analyses. We used non-negative matrix factorisation
employing the R package deconstructSigs (v1.8.0) to decompose from whole exome
SNV calls the 30 signatures of the COSMIC mutational signature matrix57. TGCT
tumours were analysed jointly, grouped at various levels by stage, histology, pla-
tinum response and dataset. Tumours were analysed at an individual level only
where total SNV count ≥ 50. To compare the distribution of COSMIC signatures in
TGCT to 32 other cancer types within the TCGA cancer project we used
mSignatureDB58.
Somatic copy number calling (ICR2). CNV calls for the ICR2 series for con-
stitutional and tumour-derived DNA were produced using the OncoSCan CNV
Plus Assay (Applied Biosystems, Waltham, MA, USA), which uses molecular
inversion probe (MIP) technology with a genome-wide resolution of 300 kb and is
optimised for use with highly degraded FFPE DNA samples59. Assays were pre-
pared as per the manufacturer’s recommendations. Arrays were stained and
washed using the GeneChip® Fluidics Station and loaded onto a GeneChip®
Scanner (Affymetrix, Santa Clara, CA) where fluorescence intensity was scanned to
generate array images (DAT files). Array fluorescence intensity data (CEL) files
were generated and used to produce OSCHP-TuScan files with the OncoScan®
Console software (v1.3) using the FFPE Analysis including Matched Normal
workflow and the appropriate annotation files.
Somatic copy number calling (TCGA, ICR1, DFCI). TCGA SNP 6.0 array data
were obtained in the form of CEL files the GDC legacy archive at https://portal.gdc.
cancer.gov/legacy-archive/search/f. PENNCNV-Affy (v1.0.3) was used to generate
LogR and BAF values following the recommended user guide steps 1.1, 1.2 and 1.4.
Raw, non-integer allele-specific copy number calls were retained and allele-specific
copy number analysis, ploidy and purity estimates of tumour samples were
obtained using ASCAT (v2.1.1) using the R script ASCAT_fromCELfiles.R at
GitHub. Allele specific somatic copy number calling, ploidy and purity estimates
were obtained from WES data for the ICR1 and DFCI datasets as previously
described12. The X chromosome was excluded from all analyses.
Analyses for aneuploidy. The fraction of the genome affected by aneuploidy was
calculated by dividing the sum of the total number of bases within segments
showing copy number changes (relative to ploidy rounded to nearest integer)
divided by the total number of bases across all segments. Arm level events were
called from segmented log2 copy ratio data using GISTIC (v2.0)60 via Gene-
Pattern61. Arm level and focal analyses were performed using the default settings.
Arm level and focal events were called as present if > absolute value of 0.1. Arm
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level aneuploidy score was calculated by summing the number of autosomal arm
level events within each tumour sample to generate a score between 0 and 39,
reflecting events covering both the long and short arms of the non-acrocentric
chromosomes and the long arms only of the acrocentric chromosomes (13, 14, 15,
21 and 22). Comparisons were performed on fraction of genome aneuploid and
arm level aneuploidy scores, respectively, using multiple linear regression, with the
aneuploidy measure as the continuous outcome and categorical predictors com-
prising dataset (ICR1, ICR2, DFCI, TCGA), sample site (primary, metastatic),
platinum response (sensitive/unselected, resistant) and histology (seminoma,
nonseminoma). Analysis was performed using the lm() function from the R
package stats (v3.5.1). Supplementary to these analyses, we used an exact, dis-
tribution free method using the lmp() function from the R package lmPerm
(v2.1.0) to confirm associations independently of the underlying data distribution.
Fisher’s exact test was performed in order to compare the number of events
between (a) primary TGCT tumours with platinum-sensitive vs. platinum-resistant
disease and (b) between primary and metastatic tumours from patients with pla-
tinum resistant disease. Associations at a nominally statistically significant p value
of <0.05 were further analysed by multivariable logistic regression. These analyses
were performed in a subset of 183 tumours with purity estimates ≥ 0.4: included
samples comprised a lower proportion of seminomas (32%) and platinum sensi-
tive/unselected tumours (71%) compared to those excluded from these analyses
(54% and 83%, respectively).
Copy number signature identification. We sought evidence for the presence of
somatic copy number signatures previously deliniated in ovarian cancer in TGCT
using the approach described in ref. 27. We utilised the genome-wide distribution
of the following six different copy number features: (i) segment size, the bp length
for each segment; (ii) breakpoint count per 10 MB, the number of breakpoints in
10 MB sliding windows across the genome; (iii) change-point copy number, the
absolute difference between adjacent copy number segments; (iv) segment copy
number, the absolute copy number of the segment; (v) breakpoint count per
chromosome arm, the number of breaks per chromosome arm; (vi) length of
segments with oscillating copy number, the number of contiguous copy number
segments switching between two copy number states, rounded to nearest integer
state. In ref. 27, the density distributions of these six genomic features were sepa-
rated out into a total of 36 distinct components using mixture modelling on high
quality absolute CN profiles from 91 whole genome sequenced ovarian cancer
tumours: Gaussian mixture models were used for features i, iii and iv whilst
Poisson mixture models were used for features ii, v and vi, with the number of
components selected based on lowest Bayesian Information Criterion. We took
these 36 distinct components, and for each copy number event identified in a
TGCT sample, we computed the posterior probability of that event belonging to a
component. For each individual TGCT sample, these posterior event vectors were
summed resulting in a sum-of-posterior probabilities vector, which were combined
in a patient-by-component sum-of-posterior probabilities matrix. The R package
NMF (v0.21.0) was used to deconvolute the patient-by-component sum-of-pos-
teriors matrix into a patient-by-signatures matrix and a signature-by-component
matrix. Non-integer copy number values were used in all analyses, as some of the
signatures are dependent on these values. Low purity samples (cellularity < 40%)
were not included in these analyses as signature quantification in such samples is
insufficiently reliable. Two-tailed Pearson’s correlation was computed between the
signature-by-component weight matrices between each of datasets using the cor.
test() function using the R package stats (v3.5.1). These analyses were performed
on copy number calls from TGCT samples from the TCGA series (n= 105) and
the ICR1 series (n= 19) and compared with copy number calls from 415 SNP array
profiling of ovarian cancer cases as part of TCGA as derived in ref. 27.
Gene expression data. RSEM gene expression data for the TCGA cohort was
obtained via the firehose browser51. We used the R package edgeR (v3.24.3) to
calculate log2 ratio reads per kilobase million (RPKM) values, filtering out lowly
expressed genes (<2 reads per million in >90% of samples). Data were normalised
using the calcNorm function, which normalises for RNA composition via scaling
factors for library sizes that minimise the log-fold changes between samples for the
majority of genes.
CN signature exposure comparisons and correlations. We compared CN sig-
nature exposure values between cases according to molecular features (presence/
absence of mutation in KIT, presence/absence of mutation RAS pathway genes
(KRAS, NRAS)), via Wilcoxon signed rank test using the wilcox.test() function
implemented in the R package stats (v3.5.1). False discovery rate was controlled for
via the Benjamini-Hochberg method. We analysed correlation of age, log2 ratio
RPKM, chromosome/gene copies with CN signature exposures. Pearson correla-
tion coefficients were calculated using the cor.test() function from the R package
stats (v3.5.1).
Force calling SNVs. To compare presence/absence of mutations between different
tumours from the same patient, we looked for evidence of a particular variant
called in a particular tumour for its presence, even at low allelic fraction, in all other
tumours from the same patient. The strong prior of having been detected de novo
in one tumour enables more sensitive detection in a second related tumour; a
method termed force-calling62. We used the overlap of calls from MuTect,
MuTect2 and Strelka as described above to generate an aggregate set of somatic
SNVs for each patient. We then used SAMtools to count the number of reads
supporting the reference and alternate alleles at those sites in their matched
samples. Reads were considered if they were from unique pairs, had a variant base
quality of ≥20 and a read quality of ≥5. Two supporting bases were required to
consider the variant present in a matched tumour, whilst less than two supporting
bases at a minimum of 50× were required to consider the variant absent. Variants
were classified as truncal if they were present in all tumour samples available from
an individual, primary only if they were confined to the primary tumour and
metastasis only if they were confined to the metastatic tumour(s) from a given case.
Gene set enrichment analysis was performed on nonsynonymous mutations
identified in each category using g:Profiler63 (rev 1760) and adjusted for multiple
tests using a g:SCS corrected threshold of p < 0.05.
Phylogenetic trees. Log2 ratio and B-allele frequency intensity data from the
OncoSCan CNV Plus Assay were filtered so that only informative probes (i.e.,
those with a heterozygous genotype) at copy neutral regions within the matched
normal sample were retained for analysis. We performed joint segmentation on
tumour samples grouped by case using the asmultipcf function in the R package
ASCAT (v2.1.1). Phylogenetic trees were constructed from major and minor copy
number calls from ASCAT (capped at a maximum of 4n) using the nearest
neighbour joining method in MEDICC28,29. Tree phylogenies were rooted to an
assumed pure diploid outgroup with no copy number changes.
Data availability
The ICR2 WES and MIP data files are available from EGA (accession:
EGAS00001003811). The DFCI WES data files are available from dbGaP (phs000923.v1.
p1). TCGA SNV (TGCT Mutation Packager Calls Level 3) and RSEM (TGCT RSEM
genes normalized data Level 3) data are available via the firehose browser (https://gdac.
broadinstitute.org/). TCGA SNP array data (Affymetrix SNP Array 6.0 CEL files) are
available from the GDC Legacy Archive (https://portal.gdc.cancer.gov/legacy-archive/
search/f). SNV calls from the MSK and FDM datasets and CN calls from the DFCI and
ICR1 are available from their respective publications. The remaining data are within the
supplementary files or are available from the authors upon reasonable request.
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